Abstract:What's new? Stress‐induced expression of peroxiredoxin 1 (PRDX1) is suspected of facilitating the progression of oral squamous cell carcinoma (OSCC). The role of PRDX1 in OSCC, however, remains uncertain. Here, the authors investigated the effect of PRDX1 on OSCC progression via cytoskeletal remodeling, a process fundamental to tumor metastasis. Analyses show that PRDX1 interacts with Cofilin, specifically inhibiting serine 3 phosphorylation. In a tongue cancer xenograft mouse model, these effects were found to promote cytoskeletal reconstruction and to accelerate cell migration. The findings identify a contributory role for PRDX1 in OSCC progression and highlight PRDX1 as a potential therapeutic target. Peroxiredoxin 1 (PRDX1) is an important member of the peroxiredoxin family (PRDX) and is upregulated in a variety of tumors. Previous studies have found that high PRDX1 expression is closely related to the metastasis of oral squamous cell carcinoma (OSCC), but the specific molecular mechanism is elusive. To elucidate the role of PRDX1 in the metastasis process of OSCC, we evaluated the expression of PRDX1 in OSCC clinical specimens and its impact on the prognosis of OSCC patients. Then, the effect of PRDX1 on OSCC metastasis and cytoskeletal reconstruction was explored in vitro and in nude mouse tongue cancer models, and the molecular mechanisms were also investigated. PRDX1 can directly interact with the actin‐binding protein Cofilin, inhibiting the phosphorylation of its Ser3 site, accelerating the depolymerization and turnover of actin, promoting OSCC cell movement, and aggravating the invasion and metastasis of OSCC. In clinical samples and mouse tongue cancer models, PRDX1 also increased lymph node metastasis of OSCC and was negatively correlated with the phosphorylation of Cofilin; PRDX1 also reduced the overall survival rate of OSCC patients. In summary, our study identified that PRDX1 may be a potential therapeutic target to inhibit OSCC metastasis.

PRDX1 inhibits ferroptosis by binding to Cullin-3 as a molecular chaperone in colorectal cancer

Cullin-5 Neddylation-Mediated NOXA Degradation is Enhanced by PRDX1 Oligomers in Colorectal Cancer

Knockdown of PRDX2 Sensitizes Colon Cancer Cells to 5-FU by Suppressing the PI3K/AKT Signaling Pathway.

Identification and Verification of PRDX1 As an Inflammation Marker for Colorectal Cancer Progression.

Dual Role of PRDX1 in Redox-Regulation and Tumorigenesis: Past and Future.

Overexpression of Peroxiredoxin 2 Inhibits TGF-β1-induced Epithelial-Mesenchymal Transition and Cell Migration in Colorectal Cancer

Transcription Factor FXR Activates DHRS9 to Inhibit the Cell Oxidative Phosphorylation and Suppress Colon Cancer Progression

NPM1 promotes cell proliferation by targeting PRDX6 in colorectal cancer

&Lt;p>silencing of Peroxiredoxin 1 Inhibits the Proliferation of Esophageal Cancer Cells and Promotes Apoptosis by Inhibiting the Activity of the PI3K/AKT Pathway</p>

Cullin-9/p53 Mediates HNRNPC Degradation to Inhibit Erastin-Induced Ferroptosis and is Blocked by MDM2 Inhibition in Colorectal Cancer

GPR37 promotes colorectal cancer against ferroptosis by reprogramming lipid metabolism via p38-SCD1 axis

PRDX6 dictates ferroptosis sensitivity by directing cellular selenium mobilization

Silencing of PRDX2 Inhibits the Proliferation and Invasion of Non-Small Cell Lung Cancer Cells

New insights into the roles of peroxiredoxins in cancer

Peroxiredoxin 1 regulates crosstalk between pyroptosis and autophagy in oral squamous cell carcinoma leading to a potential pro-survival

Identification of PRDX6 As a Regulator of Ferroptosis

The interaction of PRDX1 with Cofilin promotes oral squamous cell carcinoma metastasis

Suppressing the KIF20A/NUAK1/Nrf2/GPX4 signaling pathway induces ferroptosis and enhances the sensitivity of colorectal cancer to oxaliplatin

Tumoral Malignancy Decreases Coupled with Higher ROS and Lipid Peroxidation in HCT116 Colon Cancer Cells upon Loss of PRDX6

Peroxiredoxin 2 is Essential for Maintaining Cancer Stem Cell-Like Phenotype Through Activation of Hedgehog Signaling Pathway in Colon Cancer

Cuproptosis-Related Gene FDX1 Suppresses the Growth and Progression of Colorectal Cancer by Retarding EMT Progress